Ovarian Cancer
Preface

If there is one aspect of current cancer research that represents a major challenge in both novice and experienced researchers, it is the rapid advance in our understanding of the disease. Researchers can be required to switch from analysis of gene expression to kinetics of protein activation, from genetic studies to the analysis of protein function. Cancers are highly complex disease systems and researchers aiming to understand the functioning of cancer systems require access to a wide range of laboratory techniques from a broad range of research disciplines. Increasingly, however, published methods are incomplete or refer back to a series of previous publications each containing only a small part of the complete protocol. The aim of Ovarian Cancer: Methods and Protocols is to provide for ovarian cancer researchers in the first instance, a laboratory handbook that will facilitate research into cancer systems by providing a series of expert protocols, with proven efficacy, across a broad range of technical expertise. Thus, there are sections on tumor genetics and cellular signal transduction, as well as sections on apoptosis and RNA analysis.

The value of Ovarian Cancer: Methods and Protocols to the ovarian cancer researcher will, I trust, be considerably enhanced by (1) the provision of a series of overviews relating to the biology, diagnosis, and treatment of this important neoplasm, and (2) the provision of a series of technical overviews introducing each part that provides an expert review of the applications and pitfalls of the various techniques included.

Ovarian Cancer: Methods and Protocols aims to provide a resource for both the novice scientist/clinician coming to grips with laboratory-based research for the first time, as well as for those more experienced investigators seeking to diversify their technological base. Often, we are constrained less by our ideas than by our abilities to carry forward those ideas using different technologies.

No volume can exhaustively cover every aspect of biological research, and there will be gaps that one or another research group will identify. Each section could readily be expanded (and in some cases has been) into a book in its own right. However, I have sought to include a spectrum of techniques that will allow the acquisition of key skills in each area covered. The aim is to give the researcher an understanding of the technical issues covered in each section such that they can then extrapolate their expertise into salient techniques in these areas.

As with all volumes in the Methods in Molecular Medicine series, clear instructions in the performance of the various protocols is supplemented by additional technical notes that provide valuable insights into the working of the technique in question. Though often brief, these notes provide essential details that allow a successful outcome.

I would like to express my gratitude to all those who have contributed to this volume, who have been patient over the period required to collate their contribu-
tions. I am also grateful to Professor John Walker for his encouragement and guidance as series editor. Finally, I would like to thank my wife, Dorothy for patiently proofreading manuscripts and for being understanding on the many occasions when I arrived home late during the preparation of this volume.

John M. S. Bartlett
Contents

Preface ............................................................................................................. v
Contributors .................................................................................................... ix

PART I. INTRODUCTION TO OVARIAN CANCER
1 The Epidemiology of Ovarian Cancer
   Emily Banks ............................................................................................... 3
2 Familial Ovarian Cancer
   Ronald P. Zweemer and Ian J. Jacobs ....................................................... 13
3 The Molecular Pathogenesis of Ovarian Cancer
   S. E. Hillary Russell .................................................................................. 25
4 Alterations in Oncogenes, Tumor Suppressor Genes,
   and Growth Factors Associated with Epithelial Ovarian Cancers
   Robert C. Bast, Jr. and Gordon B. Mills .................................................... 37
5 Pathological Assessment of Ovarian Cancer
   Alistair R. W. Williams ............................................................................. 49
6 Tumor Markers in Screening for Ovarian Cancer
   Steven J. Skates, Ian J. Jacobs, and Robert C. Knapp .............................. 61
7 Primary Surgical Management of Ovarian Cancer
   Dennis S. Chi and William J. Hoskins ...................................................... 75
8 Recent Insights into Drug Resistance in Ovarian Cancer
   Thomas C. Hamilton and Steven W. Johnson ........................................... 89

PART II. TUMOR MARKERS
9 Markers of Tumor Burden: An Overview
   Joseph E. Roulston .................................................................................... 109
10 Bioactive Interleukin-6 Levels in Serum and Ascites as
    a Prognostic Factor in Patients with Epithelial Ovarian Cancer
   Günther Gastl and Marie Plante ............................................................... 121
11 ELISA-Based Quantification of p105 (c-erb-B2, HER2/neu) in Serum
    of Ovarian Carcinoma
   Harald Meden, Arjang Fattahi-Meibodi, and Dagmar Marx ....................... 125
12 Enzyme Immunoassay of Urinary β-core Fragment of Human Chorionic
   Gonadotropin as a Tumor Marker for Ovarian Cancer
   Ryuichiro Nishimura, Tamio Koizumi, Hiranmoy Das,
   Masayuki Takemori, and Kazuo Hasegawa ............................................. 135

PART III. MODEL SYSTEMS
13 Ovarian Cancer Models: Technical Review
   Simon P. Langdon, Joanne Edwards, and John M. S. Bartlett ................. 145
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>Establishment of Ovarian Cancer Cell Lines</td>
<td>Simon P. Langdon and Sandra S. Lawrie</td>
<td>155</td>
</tr>
<tr>
<td>15</td>
<td>Subcloning of Ovarian Cancer Cell Lines</td>
<td>Thomas W. Grunt</td>
<td>161</td>
</tr>
<tr>
<td>16</td>
<td>Culture and Characterization of Human Ovarian Surface Epithelium</td>
<td>Nelly Auersperg and Sarah L. Maines-Bandieria</td>
<td>169</td>
</tr>
<tr>
<td>17</td>
<td>MTT Growth Assays in Ovarian Cancer</td>
<td>Daniel M. Spinner</td>
<td>175</td>
</tr>
<tr>
<td>18</td>
<td>In Vitro Invasion Assays</td>
<td>Setsuko K. Chambers</td>
<td>179</td>
</tr>
<tr>
<td>19</td>
<td>p53 Transfectants in Ovarian Cancer</td>
<td>Faina Vikhanskaya and Massimo Broggini</td>
<td>187</td>
</tr>
<tr>
<td>20</td>
<td>Estrogen-Responsive Ovarian Cancer Xenografts</td>
<td>Alison A. Ritchie and Simon P. Langdon</td>
<td>193</td>
</tr>
<tr>
<td>21</td>
<td>The Use of Matrigel in the Establishment of Ovarian Carcinoma</td>
<td>Peter Mullen and Simon P. Langdon</td>
<td>199</td>
</tr>
<tr>
<td></td>
<td><strong>PART IV. CYTOGENETICS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Cytogenetics of Ovarian Cancer: Technical Overview</td>
<td>Thomas Liehr</td>
<td>207</td>
</tr>
<tr>
<td>23</td>
<td>Interphase Cytogenetics in Frozen Ovarian Tumor Tissue</td>
<td>Thomas Liehr</td>
<td>215</td>
</tr>
<tr>
<td>24</td>
<td>Interphase Cytogenetics in Paraffin-Embedded Ovarian Tissue</td>
<td>Susann Neubauer and Thomas Liehr</td>
<td>223</td>
</tr>
<tr>
<td>25</td>
<td>Rapid Identification of Chromosomes Using Primed In Situ Labeling (PRINS)</td>
<td>Gopal Rao V. N. Velagaleti</td>
<td>229</td>
</tr>
<tr>
<td>26</td>
<td>Gene Amplification of c-ermB-2 Detected by FISH</td>
<td>S. Robert Young, Wei-Hua Liu, and Zong-Ren Wang</td>
<td>237</td>
</tr>
<tr>
<td>27</td>
<td>Chromosome Microdissection for Detection of Subchromosomal Alterations by FISH</td>
<td>Xin-Yuan Guan and Jeffrey M. Trent</td>
<td>247</td>
</tr>
<tr>
<td>28</td>
<td>Quantitation of FISH Signals in Archival Tumors</td>
<td>Amanda D. Watters and John M. S. Bartlett</td>
<td>253</td>
</tr>
<tr>
<td>29</td>
<td>Comparative Genomic Hybridization for the Analysis of Unbalanced Chromosomal Abnormalities in Ovarian Cancer</td>
<td>Lucy J. Curtis</td>
<td>261</td>
</tr>
<tr>
<td></td>
<td><strong>PART V. MOLECULAR GENETIC IMBALANCES IN OVARIAN TUMORS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Molecular Genetics of Ovarian Cancer: A Technical Overview</td>
<td>William Foulkes and Andrew N. Shelling</td>
<td>273</td>
</tr>
<tr>
<td>31</td>
<td>Extraction of DNA from Microdissected Archival Tissues</td>
<td>James J. Going</td>
<td>291</td>
</tr>
</tbody>
</table>
Contents

32 RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene
Bernd Muhlenweg, Andreas SchneIzer, Beyhan Türkmen, Ernst Lengyel, Ute Reuning, Henner Graeff, Manfred Schmitt, and Viktor Magdolen .......................................................... 299

33 PCR Microsatellite Analysis of LOH in Ovarian Tumors
Jayne Devlin and Margaret A. Knowles .................................................... 307

34 Molecular Genetic Analysis of Flow-Sorted Ovarian and Microdissected Ovarian Tumor Cells: Improved Detection of Loss of Heterozygosity
Edwin C. A. Abeln and Willem E. Corver .................................................. 315

35 SSCP and Sequence Analysis of p53 Mutation in Ovarian Tumors
Anil K. Sood and Richard E. Buller .......................................................... 323

36 Multiplex PCR (MPCR) Screening Can Detect Small Intragenic p53 Deletion and Insertion Mutations
Ingo B. Runnebaum and Shan Wang-Gohrke ............................................. 329

37 Transfer of Human Chromosome 3 to an Ovarian Carcinoma Cell Line Identifies Regions Involved in Ovarian Cancer
Paola Rimessi and Francesca Gualandi ..................................................... 337

38 Double-and Competitive-Differential PCR for Gene Dosage Quantitation
Burkhard Brandt, Alf Beckmann, Antje Roetger, and Frank Gebhardt ........................................................................ 347

39 One Dimensional Genome Scanning—Detection of Genomic Changes in Ovarian Carcinoma
Anthony Magliocco and Murray Brilliant .................................................. 357

40 Mapping of Tumor Suppressor Genes in Ovarian Cancer
Ian G. Campbell and Emma J. Bryan ....................................................... 365

41 Detection of the Replication Error Phenotype in Ovarian Cancer—PCR Analysis of Microsatellite Instability
Gillian L. Hirst and Robert Brown ............................................................ 375

42 Immunostaining Human Paraffin-Embedded Sections for Mismatch Repair Proteins
Melanie Mackean and Robert Brown ......................................................... 383

43 Quantitative PCR Detection of c-erbB-2 Gene Amplification
Karl Dobianer, Michael Medl, and Jürgen Spona ....................................... 389

PART VI. mRNA ANALYSIS

44 mRNA Analysis: A Technical Overview
John M. S. Bartlett .................................................................................. 399

45 In Situ Hybridization Detection of TGR-β mRNA
Anders Gobl and Rudi Henriksen .............................................................. 411

46 mRNA Detection by In Situ RT-PCR
H. Anne Waller and A. Kay Savage ......................................................... 417
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors/Contributors</th>
</tr>
</thead>
<tbody>
<tr>
<td>47</td>
<td>RNase Protection Assay Analysis of mRNA for TGFβ1-3 in Ovarian Tumors</td>
<td>John M. S. Bartlett</td>
</tr>
<tr>
<td>48</td>
<td>RT-PCR Quantitation of HSP60 mRNA Expression</td>
<td>Raymond P. Perez, Lakshmi Pendyala, Zeyad Elakawi, and Mahmoud Abu-hadid</td>
</tr>
<tr>
<td>49</td>
<td>The Effects of Butyrate and the Role of c-myc in N.1 Ovarian Carcinoma Cells Determined by Northern Blotting</td>
<td>Georg Krupitza</td>
</tr>
<tr>
<td>50</td>
<td>Differential Display</td>
<td>Grant C. Sellar, Genevieve J. Rabiasz, Barbara Smith, and Jennifer Southgate</td>
</tr>
</tbody>
</table>

**PART VII. PROTEIN EXPRESSION**

| 51   | Measurement of Protein Expression: A Technical Overview                                     | Jonathan R. Reeves and John M. S. Bartlett                                          |
| 52   | Measurement of IGF-1 Receptor Content in Tissues and Cell Lines by Radioimmunoassay (RIA) and ELISA Techniques | Eberhard P. Beck, Laura Sciacco, Giuseppe Pandini, Wolfram Jaeger, and Vincenzo Pezzino |
| 53   | Radioreceptor Measurement of ER/PR                                                          | Giovanni Scambia, Gabriella Ferrandina, G. D'Agostino, A. De Dilectis, and Salvatore Mancuso |
| 54   | nm23 Protein Expression by Western Blotting in Patients with Epithelial Ovarian Carcinoma    | Giovanni Scambia, Maria Marone, Gabriella Ferrandina, Gabriella Macchia, and Salvatore Mancuso |
| 55   | Detection and Quantitation of Matrix Metalloproteases by Zymography                         | Thomas M. Leber and Rupert P. M. Negus                                                |
| 56   | Simultaneous Flow Cytometric Detection of DNA and Cellular Protein Molecules                | Willem E. Corver and Cees J. Cornelisse                                               |
| 57   | c-erbB-2 Immunohistochemistry in Paraffin Tumors                                             | Gamal H. Eltabbakh                                                                    |
| 58   | Quantitative Immunohistochemistry of Estrogen and Progesterone Receptor Positivity in Ovarian Tumors: A Rapid and Reliable Stereological Approach | Gerrit A. Meijer, Paul J. van Diest, Jane Brugghe, and Jan P. A. Baak                |
| 59   | Radioimmunohistochemistry: Quantitative Analysis of Cell Surface Receptors in Frozen Sections | Jonathan R. Reeves                                                                    |

**PART VIII. SIGNAL TRANSDUCTION**

| 60   | Signal Transduction: A Technical Overview                                                  | M. Jane Arboleda and Dennis J. Slamon                                                |
Immunoprecipitation to Determine JAK Kinase Activation in Response to Interleukins in Ovarian Cancer

Takashi Murata ................................................................. 567

Detection of ErbB Receptor Family Tyrosyl Phosphorylation in Ovarian Carcinoma Cells

Anne W. Hamburger .......................................................... 571

Phosphotyrosine Kinase Assays as a Prescreen for Inhibitors of EGFr

Joanne Edwards and John M. S. Bartlett ................................ 577

Direct Kinase Assay Screening for Inhibitors of MAP Kinase

Joanne Edwards and John M. S. Bartlett ................................ 583

Phosphatidylinositol Kinase Activity in Ovarian Cancer Cells

Atsushi Imai, Hiroshi Takagi, Atsushi Takagi, and Teruhiko Tamaya .................................................. 589

Induction of c-fos Gene Expression by Urokinase-Type Plasminogen Activator in Human Ovarian Carcinoma Cells

Inna Dumler ............................................................................. 597

Phosphotyrosine Phosphatase Activity in Ovarian Carcinoma Cells: Stimulation by GnRH in Plasma Membrane

Atsushi Imai, Shinji Horibe, Atsushi Takagi, and Teruhiko Tamaya .................................................... 601

Phosphatidylinositol 4-Kinase Assay in Ovarian Carcinoma Cells

Seiji Isonishi, Aiko Okamoto, Kazunori Ochiai, Yoshio Saito, and Kazuo Umezawa ..................................... 607

Calcium Mobilization in Ovarian Cancer Cells in Response to Lysophospholipids

Yan Xu and Derek S. Damron ................................................... 611

Compartmentalized Protein Kinase C Activation in Ovarian Carcinoma Cells

Alakananda Basu and Giridhar R. Akkaraju ................................ 621

A Novel and Simple Method to Assay the Activity of Individual Protein Kinases in a Crude Tissue Extract

Basem S. Goueli, K. Hsiao, and Said A. Goueli .......................................................... 633

Photoaffinity Detection of cAMP Binding Proteins in Ovarian Cancer

David J. Burns and Martin J. Hulme ........................................... 645

PART IX. APOPTOSIS

Apoptosis: A Technical Overview

Susan M. Quirk ........................................................................ 651

Detection of Low Levels of DNA Fragmentation in Ovarian Carcinoma Cells

Amanda J. McIlwrath .............................................................. 659

Measurement of Apoptotic Cells by Flow Cytometry (Tunnel Assay)

Michael G. Ormerod ............................................................. 665

Detection of Apoptosis in Ovarian Cells In Vitro and In Vivo Using the Annexin V-Affinity Assay

Manon van Engeland, Stefan M. van den Eijnde, Thijs van Aken, Christl Vermeij-Keers, Frans C. S. Ramaekers, Bert Schutte, and Christl P. M. Reutelingsperger .................................................. 669
Contents

Use of Diphenylamine in the Detection of Apoptosis
Randall K. Gibb and Cicek Gercel-Taylor .................................................. 679

Activation of Caspase Protease During Apoptosis in Ovarian Cancer Cells
Zhihong Chen, Mikihiko Naito, Tetsuo Mashima, Seimiya Hiroyuki, and Takashi Tsuruo ................................................................. 681

Differential Expression of Apoptosis-Associated Genes bax and bcl-2 in Ovarian Cancer
Dagmar Marx and Harald Meden ................................................................... 687

DNA-Dependent Protein Kinase in Apoptosis
John J. Turchi ................................................................................................ 693

Detection of Telomerase Activity by PCR-Based Assay
Satoru Kyo .................................................................................................... 701

PART X. IMMUNO AND GENE THERAPY PROTOCOLS

Immunological and Gene Therapy for Ovarian Cancer: A Technical Overview
Charles Gourley and Hani Gabra ................................................................ 713

Developing Anti-HER2/neu Single-Chain Fv Fragments from Phage Display Libraries
Gregory P. Adams and Robert Schier .................................................................. 729

Direction of the Recognition Specificity of Cytotoxic T Cells Toward Tumor Cells by Transduced, Chimeric T-Cell Receptor Genes
Martina Maurer-Gebhard, Marc Azémar, Uwe Altenschmidt, Matjaz Humar, and Bernd Groner ................................................................. 749

Eradication of c-erbB-2 Positive Ovarian Cancer Cells Mediated by Intracellular Expression of Anti c-erbB-2 Antibody
Jessy Deshane, Ronald D. Alvarez, and Gene P. Siegal ...................................... 757

c-erbB-2 Antisense Oligonucleotides Inhibit Serum-Induced Cell Spreading of Ovarian Cancer Cells
Kai Wiechen .................................................................................................... 769

E1A-Mediated Gene Therapy
Mien-Chie Hung, Duen-Hwa Yan, and Su Zhang .............................................. 775

p53 Adenovirus as Gene Therapy for Ovarian Cancer
Jennifer L. Carroll, J. Michael Mathis, Maria C. Bell, and Joseph T. Santoso ................................................................. 783

Bispecific Antibody MDX-210 for Treatment of Advanced Ovarian and Breast Cancer
Peter A. Kaufman, Paul K. Wallace, Frank H. Valone, Wendy A. Wells, Vincent A. Meoli, and Mark S. Ernstoff .................................................. 793

Index ........................................................................................................... 807
Contributors

EDWIN C. A. ABELN • Centraal Bureau voor Schimmelcultures, RNAAS Institute, Baarn, The Netherlands
MAHMOUD ABU-HADID • Division of Medicine, Roswell Park Cancer Institute, Buffalo, NY
GREGORY P. ADAMS • Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA
GIYIDHAR R. AKKARAJU • Department of Molecular Biology and Immunology, University of North Texas Health Science Center, Fort Worth, TX
UWE ALTENSCHMIDT • Institute for Experimental Cancer Research, Tumor Biology Center, Freiburg, Germany
RONALD D. ALVAREZ • Departments of Obstetrics and Gynecology, University of Alabama, Birmingham, AL
M. JANE ARBOLEDA • Department of Medicine, Division of Haematological Oncology, UCLA School of Medicine, University of Califorina, Los Angeles, CA
NELLY AUERSPERG • Department of Obstetrics and Gynecology, University of British Columbia, BC Women’s Hospital, Vancouver, Canada
GIYIDHAR R. AKKARAJU • Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, PA
MARC AZÉMAR • Institute for Experimental Cancer Research, Tumor Biology Center, Freiburg, Germany
JAN P. A. BAAK • Department of Quantitative Pathology, Academisch Ziekenhuis VrijeUniversiteit De Boelelaan, Amsterdam, The Netherlands
EMILY BANKS • ICRG Cancer Epidemiology Unit, Radcliffe Infirmary, Oxford, UK
JOHN M. S. BARTLETT • Department of Surgery, Glasgow Royal Infirmary, Glasgow, UK
ROBERT C. BAST, JR. • Department of Obstetrics and Gynecology, Duke University Medical Center, NC
ALAKANANDA BASU • Department of Molecular Biology and Immunology, University of North Texas Health Science Center, Fort Worth, TX
EBERHARD P. BECK • Leitender Oberarzt, Städtische Frauenklinik Berk, Stuttgart, Germany
ALF BECKMANN • Klinischer Chemiker, Institut für Klinische Chemie und Laboratoriumsmedizin, Münster, Germany
MARIA C. BELL • Department of Cellular Biology and Anatomy, Louisiana State University Medical Center-Shreveport, Shreveport, LA
BURKHARD BRANDT • Klinischer Chemiker, Institut für Klinische Chemie und Laboratoriumsmedizin, Münster, Germany
MURRAY BRILLIANT • Department of Pathology, Royal University Hospital Saskatoon, Saskatchewan, Canada
MASSIMO BROGGINI • Laboratory of Cancer Pharmacology, Mario Negri Institute for Pharmacological Research, Milan, Italy
ROBERT BROWN • CRC Department of Medical Oncology, Beatson Laboratories, Glasgow University, Glasgow, UK
JANE BRUGGHE • Department of Quantitative Pathology, Academisch Ziekenhuis VrijeUniversiteit De Boelelaan, Amsterdam, The Netherlands
EMMA J. BRYAN • Department of Obstetrics and Gynecology, University of Southampton Princess Anne Hospital, Southampton, UK
DAVID J. BURNS • Breast Cancer Research Unit, Western General Hospital, Edinburgh, Scotland
RICHARD E. BULLER • Department of Pharmacology, University of Iowa Hospitals and Clinics, Iowa City, IA
IAN G. CAMPBELL • Department of Obstetrics and Gynecology, University of Southampton Princess Anne Hospital, Southampton, UK
JENNIFER L. CARROLL • Department of Cellular Biology and Anatomy, and Obstetrics and Gynecology, Louisiana State University Medical Center-Shreveport, Shreveport, LA
SETSUKO K. CHAMBERS • Department of Obstetrics and Gynecology, Yale School of Medicine, New Haven, MA
ZHIHONG CHEN • Laboratory of Biomedical Research, Institute of Molecular and Cellular Bioscience, University of Tokyo, Tokyo, Japan
DENNIS S. CHI • Gynecology Academic Office, Gynecology Service, Memorial Sloan-Kettering Cancer Center, New York, NY
CEES J. CORNELISSE • Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands
WILLEM E. CORVER • Centraal Bureau voor Schimmelcultures, RNAAS Institute, Baarn, The Netherlands
LUCY J. CURTIS • Department of Pathology, Molecular Medicine Centre, Edinburgh University, Edinburgh, Scotland
G. D’AGOSTINO • Department of Obstetrics and Gynecology, Laboratory of Antienoplastic Pharmacology Zeneca, Catholic University of the Sacred Heart, Rome, Italy
DEREK S. DAMRON • Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH
HIRANMOY DAS • Department of Obstetrics and Gynecology, Hyogo Medical Center for Adults 13–70, Akashi, Japan
A. DE DILECTIS • Department of Obstetrics and Gynecology, Laboratory of Antienoplastic Pharmacology Zeneca, Catholic University of the Sacred Heart, Rome, Italy
JESSY DESHANE • Departments of Pathology, University of Alabama, Birmingham, AL
JAYNE DEVLIN • School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland
KARL DOBIANER • Department of Cellular Endocrinology, Ludwig Boltzmann Institute for Experimental Endocrinology, General Hospital of Vienna, Vienna, Austria
Contributors

INNA DUMLER • Charité-Franz Volhard Clinic, and Max-Delbrück Center for Molecular Medicine, Humboldt University at Berlin, Berlin, Germany

JOANNE EDWARDS • University Department of Surgery, Glasgow, Scotland

ZEYAD ELAKAWI • Division of Medicine, Roswell Park Cancer Institute, Buffalo, NY

GAMAL H. ELTABBAKH • Department of Gynecologic Oncology, Fletcher Allen Health Care/University of Vermont, Burlington, VT

MARK S. ERNSTOFF • Section of Hematology/Oncology, Dartmouth Hitchcock Medical Center, Lebanon, NH

ARJANG FATTahi-Meibodi • Department of Obstetrics and Gynecology, University of Göttingen, Göttingen, Germany

GABRIELLA FERRANDINA • Department of Obstetrics and Gynecology, Laboratory of Antienoplastic Pharmacology Zeneca, Catholic University of the Sacred Heart, Rome, Italy

WILLIAM FOULKEs • Department of Medicine, Human Genetics, and Oncology, Montreal General Hospital and Sir M. B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada

HANI GABRA • ICRG Medical Oncology Unit, Western General Hospital, Edinburgh, Scotland

GÜNTER GASTL • Department of Hematology and Oncology, University of Innsbruck, Innsbruck, Austria

FRANK GEBHARDT • Klinischer Chemiker, Institut für Klinische Chemie und Laboratoriumsmedizin, Münster, Germany

CICEK GERCEL-TAYLOR • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Louisville, Louisville, KY

RANDALL K. GIBB • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Louisville, Louisville, KY

ANDERS GOBL • Department of Internal Medicine, University of Uppsala Hospital, Uppsala, Sweden

JAMES J. GOING • Department of Pathology, University of Glasgow, Glasgow, Scotland

BASEM S. GOUELI • Department of Obstetrics/Gynecology, Jikei University School of Medicine, Tokyo Japan

SAID A. GOUELI • Department of Obstetrics/Gynecology, Jikei University School of Medicine, Tokyo Japan

CHARLES GOURLEY • Imperial Cancer Research Fund, Medical Oncology Unit, Western General Hospital, Edinburgh, Scotland

HENNER GRAEFF • Klinischer Forschergruppe der Frauenklinik der Technischen Universität München, München, Germany

BERND GRONER • Chemotherapeutisches Forschungsinstitut, Georg Speyer Haus, Frankfurt, Germany

THOMAS W. GRUNT • Department of Oncology, University Clinic of Internal Medicine, Vienna, Austria

FRANCESCA GUALANDI • Institute of Microbiology, School of Medicine, University of Ferrara, Ferrara, Italy

XIN-YUAN GUAN • Laboratory of Cancer Genetics, National Human Genome Research Unit, National Institutes of Health, Bethesda, MD
Contributors

ANNE W. HAMBURGER • Division of Cell and Molecular Biology, Greenebaum Center for Cancer Research, University of Maryland, Baltimore, MD

THOMAS C. HAMILTON • Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA

KAZUO HASEGAWA • Department of Obstetrics and Gynecology, Hyogo Medical Center for Adults 13–70, Akashi, Japan

RUDI HENRIKSEN • Department of Women’s and Children’s Health, Obstetrics and Gynecology, University of Uppsala Hospital, Uppsala, Sweden

SEMIYA HIROYUKI • Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan

GILLIAN L. HIRST • CRC Department of Medical Oncology, Beatson Laboratories, Glasgow University, Glasgow, Scotland

SHINJI HORIBE • Department of Obstetrics and Gynecology, Gifu University School of Medicine, Gifu, Japan

WILLIAM J. HOSKINS • Gynecology Academic Office, Gynecology Service, Memorial Sloan-Kettering Cancer Center, New York, NY

K. HSAIO • Signal Transduction Group, Promega, and Department of Pathology and Laboratory Medicine, University School of Medicine, Madison, WI

MARTIN J. HULME • Breast Cancer Research Unit, Western General Hospital, Edinburgh, Scotland

MATJAZ HUMAR • Institute for Experimental Cancer Research, Tumor Biology Center, Freiburg, Germany

MIEN-CHIE HUNG • Department of Cancer Biology, Section of Molecular Cell Biology and Department of Surgical Oncology, The University of Texas, Houston, TX

ATSUSHI IMAI • Department of Obstetrics and Gynecology, Gifu University School of Medicine, Gifu, Japan

SEIJI ISONISHI • Department of Obstetrics/Gynecology, Jikei University School of Medicine, Minato-ku, Tokyo, Japan

IAN J. JACOBS • Gynecology Cancer Research Unit, St. Bartholomew’s Hospital, West Smithfield, London, UK

WOLFRAM JAEGGER • Department of Obstetrics and Gynecology, University of Erlangen-Nuremberg, Universität Straße, Erlangen, Germany

STEVEN W. JOHNSON • Department of Medical Oncology, Fox Chase Cancer Centre, Philadelphia, PA

PETER A. KAUFMAN • Section of Hematology/Oncology, Dartmouth Hitchcock Medical Center, Lebanon, NH

ROBERT C. KNAPP • Division of Gynecologic Oncology, Brigham and Women’s Hospital, Boston, MA

MARGARET A. KNOWLES • ICRF Cancer Medicine Research Unit, St. James’s University Hospital, Leeds, UK

TAMIO KOIZUMI • Department of Obstetrics and Gynecology, Hyogo Medical Center for Adults 13–70, Akashi, Japan

GEORG KRUPITZKA • Department of Haematopathology, Institute of Clinical Pathology, University of Vienna, Vienna, Austria
Contributors

SATORU KYO • Department of Obstetrics and Gynecology, Kanazawa University, Kanazawa, Japan

SIMON P. LANGDON • Imperial Cancer Research Fund, Medical Oncology Unit, Western General Hospital, Edinburgh, Scotland

SANDRA S. LAWRIE • Imperial Cancer Research Fund, Medical Oncology Unit, Western General Hospital, Edinburgh, Scotland

THOMAS M. LEBER • Imperial Cancer Research Fund, Biological Therapies Laboratory, London, UK

ERNST LENGYEL • Klinischer Forschergruppe der Frauenklinik der Technischen Universität München, Muenchen, Germany

THOMAS LIEHR • Institut für Humangenetik, Jena, Germany

WEI-HUA LIU • Department of Obstetrics and Gynecology, University of South Carolina School of Medicine, Columbia, SC

GABRIELLA MACCHIA • Department of Obstetrics and Gynecology, Laboratory of Antienoplastic Pharmacology Zeneca, Catholic University of the Sacred Heart, Rome, Italy

MELANIE MACKEAN • Department of Medical Oncology, Western General Hospital NHS Trust, Edinburgh Scotland

VIKTOR MAGDOLEN • Klinischer Forschergruppe der Frauenklinik der Technischen Universität München, Muenchen, Germany

ANTHONY MAGLIOCCO • Department of Pathology, Royal University Hospital Saskatoon, Saskatchewan, Canada

SARAH L. MAINES-BANDIERA • Department of Obstetrics and Gynecology, University of British Columbia, BC Women’s Hospital, Vancouver, Canada

SALVATORE MANCUSO • Department of Obstetrics and Gynecology, Laboratory of Antienoplastic Pharmacology Zeneca, Catholic University of the Sacred Heart, Rome, Italy

MARIA MARONE • Department of Obstetrics and Gynecology, Laboratory of Antienoplastic Pharmacology Zeneca, Catholic University of the Sacred Heart, Rome, Italy

DAGMAR MARX • Department of Obstetrics and Gynecology, University of Gottingen, Gottingen, Germany

TETSUO MASHIMA • Laboratory of Biomedical Research, Institute of Molecular and Cellular Bioscience, University of Tokyo, Tokyo, Japan

J. MICHAEL MATHIS • Department of Cellular Biology and Anatomy, and Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Louisiana State University Medical Center-Shreveport, Shreveport, LA

MARTINA MAURER-GEHARD • Institute for Experimental Cancer Research, Tumor Biology Center, Freiburg, Germany

AMANDA J. McILWRATH • CRC Department of Medical Oncology, Glasgow, Scotland

HARALD MEDEN • Department of Obstetrics and Gynecology, University of Gottingen, Gottingen, Germany

MICHAEL MEDL • Department of Obstetrics and Gynecology, Lainz Medical Center, Vienna, Austria
VINCENT MEOLIO • Section of Hematology/Oncology, Dartmouth Hitchcock Medical Center, Lebanon, NH
GERRIT A. MEIJER • Department of Quantitative Pathology, Academisch Ziekenhuis VrijeUniversiteit De Boelelaan, Amsterdam, The Netherlands
GORDON B. MILLS • Department of Obstetrics and Gynecology, Duke University Medical Center, NC
TAKASHI MURATA • First Department of Internal Medicine, School of Medicine, Yokohama City University, Yokohama, Japan
BERND MÜHLENWEG • Klinischer Forschergruppe der Frauenklinik der Technischen Universität München, Muenchen, Germany
PETER MULLEN • Imperial Cancer Research Fund, Medical Oncology Unit, Western General Hospital, Edinburgh, Scotland
MIKIHIKO NAITO • Laboratory of Biomedical Research, Institute of Molecular and Cellular Bioscience, University of Tokyo, Tokyo, Japan
RUPERT P. M. NEGUS • Imperial Cancer Research Fund, Biological Therapies Laboratory, London, UK
SUSANN NEUBAUER • Klinik und Poliklinik für Strahlentherapie, Universitätsstr, Erlangen, Germany
RYUICHIRO NISHIMURA • Department of Obstetrics and Gynecology, Hyogo Medical Center for Adults 13–70, Akashi, Japan
KAZUNORI OCHIAI • Department of Obstetrics/Gynecology, Jikei University School of Medicine, Minato-ku, Tokyo, Japan
AIKO OKAMOTO • Department of Obstetrics/Gynecology, Jikei University School of Medicine, Minato-ku, Tokyo, Japan
MICHAEL G. ORMEROD • Reigate, United Kingdom
GUILSEPPE PANDINI • Istituto di Medicina Interna, Malattie Endocrine e del Metabolismo, Universita di Catania, Catania, Italy
LAKSHMI PENDYALA • Division of Medicine, Roswell Park Cancer Institute, Buffalo, NY
LAKSHMI PENDYALA • Division of Medicine, Roswell Park Cancer Center, Buffalo, NY
RAYMOND P. PEREZ • Section of Hematology/Oncology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
VINCENT PEZZINO • Istituto di Medicina Interna, Malattie Endocrine e del Metabolismo, Universita di Catania, Catania, Italy
MARIE PLANTE • Gynecology Service, L’Hotel-Dieu de Quebec, Quebec City, Canada
SUSAN M. QUIRK • Department of Animal Science, Cornell University, Ithaca, NY
GENEVIYE J. RABIASZ • Imperial Cancer Research Fund Medical Oncology Unit, Western General Hospital, Edinburgh, Scotland
FRANS C. S. RAMAEEKERS • Department of Molecular Cell Biology and Genetics, University of Maastricht, Maastricht, Netherlands
JONATHAN R. REEVES • Delaware, Ontario, Canada
UTE REUNING • Klinischer Forschergruppe der Frauenklinik der Technischen Universität München, Muenchen, Germany
CHRISTL P. M. REUTELINGSPERGER • Department of Molecular Cell Biology and Genetics, University of Maastricht, Maastricht, Netherlands
Contributors

PAOLA RIMESSI • Institute of Microbiology, School of Medicine, University of Ferrara, Ferrara, Italy

ALISON A. RITCHIE • Imperial Cancer Research Fund, Medical Oncology Unit, Western General Hospital, Edinburgh, Scotland

ANTJE ROETGER • Klinisher Chemiker, Institut für Klinische Chemie und Laboratoriumsmedizin, Münster, Germany

JOSEPH E. ROULSTON • Department of Reproductive and Developmental Sciences, The University of Edinburgh, The Royal Infirmary, Edinburgh, Scotland

INGO B. RUNNEBAUM • Molecular Biology Laboratory, Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany

S. E. HILLARY RUSSELL • Department of Oncology, The Queen’s University of Belfast, Belfast City Hospital, Belfast, Northern Ireland

YOSHIO SAITO • Department of Applied Chemistry, Faculty of Science and Technology, Keio University, Kohoku-ku, Yokohama, Japan

JOSEPH T. SANTOSO • Division of Gynecologic Oncology, University of Texas Medical Branch, Galveston, TX

A. KAY SAVAGE • Department of Histopathology, Royal Free Hospital School of Medicine, Hampstead, London

GIOVANNI SCAMBIA • Department of Obstetrics and Gynecology, Laboratory of Antienoplastic Pharmacology Zeneca, Catholic University of the Sacred Heart, Rome, Italy

ROBERT SCHIER • Xerion Pharmaceuticals GmbH, Martinsreid, Munich, Germany

ANDREAS SCHNELZER • Klinischer Forschergruppe der Frauenklinik der Technischen Universität München, Muenchen, Germany

MANFRED SCHMITT • Klinischer Forschergruppe der Frauenklinik der Technischen Universität München, Muenchen, Germany

BERT SCHUTTE • Department of Molecular Cell Biology and Genetics, University of Maastricht, Maastricht, Netherlands

LAURA SCIACCA • Istituto di Medicina Interna, Malattie Endocrine e del Metabolismo, Universita di Catania, Catania, Italy

GRANT C. SELLS • Imperial Cancer Research Fund Medical Oncology Unit, Western General Hospital, Edinburgh, Scotland

ANDREW N. SHELING • Department of Obstetrics and Gynecology, Research Centre in Reproductive Medicine, National Women’s Hospital, Auckland, New Zealand

GENE P. SIEGAL • Departments of Pathology and Biology, University of Alabama, Birmingham, AL

STEVEN J. SKATES • General Medicine Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA

DENNIS J. SLAMON • Department of Medicine, Division of Haematological Oncology, UCLA School of Medicine, University of California, Los Angeles, CA

BARBARA SMITH • Department of Biology, Jack Birch Unit of Molecular Carcinogenesis, University of York, York, UK

ANIL K. SOOD • Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA
Contributors

Jennifer Southgate • Department of Biology, Jack Birch Unit of Molecular Carcinogenesis, University of York, York, UK
Daniel M. Spinner • Abteilung Frauenheilkunde und Geburtshilfe I, Universitäts Klinik Freiburg, Freiburg, Germany
Jürgen Spona • Department of Cellular Endocrinology, Ludwig Boltzmann Institute for Experimental Endocrinology, General Hospital of Vienna, and Department of Obstetrics and Gynecology, University of Vienna, Vienna, Austria
Hiroshi Takagi • Department of Obstetrics and Gynecology, Gifu University School of Medicine, Gifu, Japan
Atsushi Takagi • Department of Obstetrics and Gynecology, Gifu University School of Medicine, Gifu, Japan
Masayuki Takemori • Department of Obstetrics and Gynecology, Hyogo Medical Center for Adults 13–70, Akashi, Japan
Teruhiko Tamaya • Department of Obstetrics and Gynecology, Gifu University School of Medicine, Gifu, Japan
Jeffrey M. Trent • Laboratory of Cancer Genetics, National Human Genome Research Unit, National Institutes of Health, Bethesda, MD
Takashi Tsuruo • Laboratory of Biomedical Research, Institute of Molecular and Cellular Bioscience, University of Tokyo, and Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan
John J. Turchi • Department of Biochemistry and Molecular Biology, School of Medicine, Wright State University, Dayton, Ohio
Beyhan Türkmén • Klinischer Forschergruppe der Frauenklinik der Technischen Universität München, Muenchen, Germany
Kazuo Umezawa • Department of Applied Chemistry, Faculty of Science and Technology, Keio University, Kohoku-ku, Yokohama, Japan
Frank H. Valone • Section of Hematology/oncology, Dartmouth Hitchcock Medical Center, Lebanon, NH
Thijs van Aken • Department of Molecular Cell Biology and Genetics, University of Maastricht, Maastricht, Netherlands
Christl Vermeij-Kee rs • Department of Molecular Cell Biology and Genetics, University of Maastricht, Maastricht, Netherlands
GopalRao V. N. Velagaleti • Division of Medical Genetics, Department of Pediatrics, University of Tennessee, Memphis, TN
Paul J. van Diest • Department of Quantitative Pathology, Academisch Ziekenhuis Vrije Universiteit De Boelelaan, Amsterdam, The Netherlands
Stefan M. van den Eijnde • Department of Molecular Cell Biology and Genetics, University of Maastricht, Maastricht, Netherlands
Manon van Engeland • Department of Molecular Cell Biology and Genetics, University of Maastricht, Maastricht, Netherlands
GopalRao V. N. Velagaleti • Division of Genetics, Department of Pediatrics, University of Texas Medical Branch, Galveston, TX
Faina Vikhanskaya • Laboratory of Cancer Pharmacology, Mario Negri Institute for Pharmacological Research, Milan, Italy
Contributors

PAUL K. WALLACE • Section of Hematology/oncology, Dartmouth Hitchcock Medical Center, Lebanon, NH

H. ANNE WALLER • Imperial College School of Medicine at St. Mary’s, Sussex Gardens, London

ZONG-REN WANG • Department of Obstetrics and Gynecology, University of South Carolina School of Medicine, Columbia, SC

SHAN WANG-GOHRKE • Molecular Biology Laboratory, Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany

AMANDA D. WATTERS • Department of Surgery, Glasgow Royal Infirmary, Glasgow, UK

WENDY A. WELLS • Section of Hematology/oncology, Dartmouth Hitchcock Medical Center, Lebanon, NH

KAI WIECHEN • Institute of Pathology, University Clinic Charite Faculty of Medicine, Humboldt University of Berlin, Berlin, Germany

ALISTAIR R. W. WILLIAMS • Department of Pathology, Edinburgh University, Edinburgh, Scotland

YAN XU • Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH

DUEN-HWA YAN • Department of Cancer Biology, Section of Molecular Cell Biology and Department of Surgical Oncology, The University of Texas, Houston, TX

S. ROBERT YOUNG • Department of Obstetrics and Gynecology, University of South Carolina School of Medicine, Columbia, SC

SU ZHANG • Department of Cancer Biology, Section of Molecular Cell Biology and Department of Surgical Oncology, The University of Texas, Houston, TX

RONALD P. ZWEEMER • Department of Obstetrics and Gynecology, University Hospital Vrije Universiteit, Amsterdam, Netherlands